Incyte (INCY)
(Delayed Data from NSDQ)
$65.87 USD
+0.50 (0.77%)
Updated Jul 19, 2024 04:00 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INCY 65.87 +0.50(0.77%)
Will INCY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INCY
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
INCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
INCY or MYGN: Which Is the Better Value Stock Right Now?
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
Other News for INCY
Most shorted S&P 500 stocks in June
Incyte to Report Second Quarter Financial Results
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Analyst Expectations For Incyte's Future